Helping you make wiser investment decisions

Pharmaceuticals, health and wellness

Takeda keeps divestment spree rolling with $1.2B sale of diabetes meds to Japanese firm Teijin

After inking a slate of geography-specific product selloffs last year, Takeda has turned back to Japan. Takeda locked up a deal to sell four Type 2 diabetes meds in Japan to local drugmaker Teijin Pharma for 133 billion Japanese yen ($1.2 billion), freeing up the company to focus on its core businesses in gastroenterology, rare […]

Perrigo’s generics split is back on the docket, thanks to $1.55B Altaris offer

Perrigo pumped the brakes on its prescription generics hive-off last year, but, now, it has a buyer locked in and expects the split to go through by summer’s end. Perrigo clinched a deal to sell its prescription generics business to Altaris Capital Partners for $1.55 million—a price analysts deemed “pretty good” under the circumstances. Once […]

Johnson & Johnson’s COVID vaccine scores FDA panel backing, setting up likely authorization

A month after Johnson & Johnson’s COVID-19 vaccine posted positive data in a phase 3 study, the shot is almost ready for prime time. Late Friday, a key panel unanimously endorsed the vaccine for emergency use and sent it to the agency for an official decision. An FDA authorization for the one-dose vaccine would provide a quick lift […]

Vials maker Stevanto plans IPO as coronavirus vaccine companies clamor for packaging: Reuters

The global pandemic promised a windfall for forward-thinking companies making products to help combat the spread of the coronavirus. Count the Stevanto Group, one of the world’s foremost makers of glass vials, among them. Since the onset of the pandemic, business has been booming at the 72-year-old Italian company, so much so that Stevanto is […]

Lilly scores $210M supply deal for newly authorized coronavirus antibody cocktail

As U.S. officials look to ramp up COVID-19 vaccinations heading into March, they’re not overlooking another pandemic-fighting tool. Eli Lilly on Friday scored a government supply deal for its newly authorized antibody cocktail, which dramatically reduced deaths and hospitalizations in a late-stage trial.  Lilly agreed to sell the U.S. government 100,000 doses of the bamlanivimab-etesevimab […]

Ready to square off with Pfizer in next-gen pneumococcal vaccines, a Merck exec says competition’s a good thing

As next-gen pneumococcal vaccines from Merck & Co. and Pfizer work through the FDA review process—and as an important CDC committee weighs data this week—a Merck exec says he embraces the competition that’s likely to follow. Ahead of Thursday’s meeting of the CDC’s Advisory Committee on Immunization Practices, Merck’s Luwy Musey, executive director in biologics and vaccines clinical research, said in an interview that […]

Novartis’ first Kesimpta ad push proffers break from relapsing MS ‘drama’

Novartis’ first TV ad for Kesimpta offers the prospect of less drama—less relapsing multiple sclerosis drama, that is. During the commercial, phrases representing that drama such as “unpredictable relapses” and “disability progression” pop up around a young woman as she goes about her day. But another issue that pops up on screen—infusion days—may cause some drama […]

Sanofi, Regeneron’s Libtayo snags lung cancer nod, taking a stab at Keytruda’s megablockbuster lead

Sanofi and Regeneron’s Libtayo is on a roll with its second FDA nod in just two weeks. And the latest green light breaks the PD-1 inhibitor out of its skin cancer comfort zone and into the competitive—and lucrative—lung cancer market, where Merck & Co.’s Keytruda reigns supreme. Libtayo won an FDA go-ahead Monday to treat patients with […]

After Pfizer deal, Sanofi offers a hand to Johnson & Johnson for COVID-19 vaccine production

Sanofi hasn’t abandoned its COVID-19 vaccine hopes despite a setback in the high-stakes race, but as it moves two different shots forward, it’s also pitching in to make doses for its usual rivals. The drugmaker on Monday inked a manufacturing tie-up with Johnson & Johnson to help produce that company’s vaccine in Europe. The deal follows a separate agreement for Sanofi […]

AbbVie settles trade secrets fight with Evolus, scoring $35M and royalties on Botox rival Jeuveau

AbbVie’s newest revenue streams come courtesy of Evolus and its Botox competitor Jeuveau.  To settle a long-running legal battle, Evolus will pay Allergan and its partner Medytox $35 million in cash, plus royalties on Jeuveau’s U.S. sales, according an Evolus SEC filing. The settlement ends all legal claims the trio had levied against one another and […]

FDA slaps import alert on India’s Shilpa after sterile injectables issues multiply

Just a few months after India-based drugmaker Shilpa Medicare found itself in the FDA’s crosshairs, the company now faces a ban on the vast majority of its products in the U.S.  The FDA slapped an import alert on Shilpa Medicare’s formulation plant in Telangana, India, according to a notice posted Thursday. The product ban comes on the heels of an […]

Fierce Pharma Asia—Takeda’s CMV drug win; Merck and Eisai’s kidney cancer showing; Botox rival Jeuveau’s settlement

Takeda laid out data showing its cytomegalovirus candidate maribavir works better than standard care at clearing out the virus in transplant recipients with refractory infections. Merck and Eisai’s Keytruda-Lenvima pairing appears to have the best data in previously untreated kidney cancer among four immuno-oncology regimens, one analyst said. An appeals court has allowed Evolus and Daewoong Pharma’s […]